Healthcare / Diagnostics & ResearchNasdaqGM
$22.80
-0.02 (-0.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $31.6M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.0%
↓Gross Margin
67.6%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+25.2%
FCF CAGR
—
FCF margin
9.3%
FCF / Net income
-1.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $379.8M · net income $-21.4M · FCF $35.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $379.8M | $379.8M | $333.8M | $280.3M | $321.8M | $296.4M | $192.2M | $127.1M | $76.6M | $48.3M | $40.6M | $28.1M | $27.3M | $22.1M | $20.5M |
| Net Income | $-21.4M | $-21.4M | $52.5M | $-190.3M | $-76.6M | $-30.7M | $-18.7M | $-22.0M | $-46.8M | $-55.5M | $-39.5M | $-13.7M | $781000.00 | $-3.5M | $-5.1M |
| EBITDA | $-4.7M | $-4.7M | $-35.8M | $-87.2M | $-61.2M | $-20.9M | $-15.5M | $-19.0M | $-11.4M | $-16.6M | $-34.4M | $-11.1M | $1.8M | $-194000.00 | $-1.3M |
| EPS | -0.40 | -0.40 | 0.93 | -3.54 | -1.44 | -0.59 | -0.40 | -0.52 | -1.31 | -2.38 | -2.39 | -1.16 | 0.10 | -3.50 | -5.01 |
| Gross Margin | 67.6% | 67.6% | 67.1% | 63.6% | 65.1% | — | — | 64.2% | 56.9% | 55.8% | — | — | — | — | — |
| Operating Margin | -6.6% | -6.6% | -16.6% | -38.2% | -24.0% | -10.0% | -11.7% | -19.3% | -20.3% | -42.0% | -91.9% | -42.4% | 4.6% | -3.9% | -11.5% |
| Net Margin | -5.6% | -5.6% | 15.7% | -67.9% | -23.8% | -10.3% | -9.7% | -17.3% | -61.1% | -114.8% | -97.1% | -48.7% | 2.9% | -16.0% | -24.7% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.07 | 0.13 | 0.09 | — | 0.00 | 0.00 | 0.00 | -2.99 | 0.06 | 0.44 | 0.13 | -0.07 | — |
| Current Ratio | 3.40 | 3.40 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $35.4M | $35.4M | $31.6M | $-27.6M | $-49.6M | — | — | — | $-6.0M | $-14.5M | $-17.1M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -7.0% | -7.0% | 13.9% | -72.8% | -17.8% | -6.6% | -6.7% | -22.2% | -48.7% | 904.3% | -202.6% | -46.5% | 1.9% | 2.4% | 3.4% |
| Valuation | |||||||||||||||
| P/E | — | — | 24.01 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 4.01 | 4.01 | 3.34 | 2.32 | 1.39 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 13.8% | 13.8% | 19.1% | -12.9% | — | 54.2% | 51.3% | 66.0% | 58.4% | 18.9% | 44.4% | 3.1% | 23.6% | 8.1% | — |
| EPS Growth | -143.0% | -143.0% | 126.3% | -145.8% | — | -47.5% | 23.1% | 60.3% | 45.0% | 0.4% | -106.0% | -1260.0% | 102.9% | 30.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.93 → -0.40
Residual
+34.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.